CEL-SCI (NYSE:CVM) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM) in a research note released on Thursday. The brokerage issued a sell rating on the stock.

CEL-SCI Stock Down 2.6 %

Shares of NYSE:CVM opened at $0.40 on Thursday. The firm has a 50 day simple moving average of $0.58 and a 200-day simple moving average of $0.92. CEL-SCI has a twelve month low of $0.36 and a twelve month high of $3.08. The company has a current ratio of 0.64, a quick ratio of 0.18 and a debt-to-equity ratio of 1.00. The company has a market capitalization of $29.52 million, a PE ratio of -0.69 and a beta of 0.65.

Institutional Trading of CEL-SCI

Several institutional investors and hedge funds have recently made changes to their positions in CVM. Geode Capital Management LLC grew its position in shares of CEL-SCI by 9.6% during the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after acquiring an additional 53,879 shares during the last quarter. Plotkin Financial Advisors LLC acquired a new position in shares of CEL-SCI during the third quarter worth about $98,000. Calton & Associates Inc. purchased a new position in shares of CEL-SCI during the 3rd quarter worth approximately $50,000. Renaissance Technologies LLC raised its position in CEL-SCI by 29.9% in the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after acquiring an additional 40,000 shares in the last quarter. Finally, Thoroughbred Financial Services LLC increased its holdings in shares of CEL-SCI by 140.9% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock valued at $158,000 after purchasing an additional 80,001 shares in the last quarter. 12.08% of the stock is owned by hedge funds and other institutional investors.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.